TREATMENT OF ORTHOPEDIC CONDITIONS

• US 20110217313A1
• Filed: 12/22/2008
• Published: 09/08/2011
• Est. Priority Date: 12/21/2007
• Status: Abandoned Application

• Current Assignee: Bradford James Duft, Colin R. Green, David L. Becker
• Original Assignee: Bradford James Duft, Colin R. Green, David L. Becker
• Inventors: Green, Colin R., Becker, David L., Duft, Bradford James
• Application Number:
  US12/809,902
• Publication Number:
  US 20110217313A1
• Time in Patent Office: Days
• US Class Current: 424/172.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/177 Receptors; Cell surface antigens; Cell surface determinants
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2320/31 Combination therapy

Abstract

Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorder, disease, or condition, and promoting post-surgical wound-healing.

Claims

1. A method of treating a subject undergoing an orthopedic procedure comprising administration of a composition comprising an anti-connexin 43 agent to a site of injury within said subject before, at the time of, or after said orthopedic procedure, wherein a surgical outcome is improved.

2. A method of claim 1, wherein the surgical outcome is improved recovery time uced pain and/or improved mobility.

3. A method of claim 1 wherein said anti-connexin 43 agent is a connexin 43 polynucleotide.

4. The method of claim 1, wherein the anti-connexin agent is an anti-connexin 43 antisense polynucleotide.

5. The method of claim 3, wherein the anti-connexin 43 polynucleotide decreases connexin 43 protein expression.

6. The method of claim 2 wherein the anti-connexin 43 polynucleotide is an siRNA or and RNAi oligonucleotide.

7. The method of claim 1 wherein the anti-connexin 43 agent is a peptide.

8. The method of claim 7 wherein the peptide is a peptidomimetic.

9. The method of claim 1, wherein the anti-connexin 43 agent is an anti-connexin 43 antibody or antigen binding fragment thereof.

10. The method of claim 11, wherein the anti-connexin 43 agent is an antibody, F(v) fragment, Fab fragment, Fab′

fragment, or F(ab′

)₂ fragment.

11. The method of claim 1, wherein the anti-connexin 43 agent inhibits or blocks intercellular communication.

12. The method of claim 1, wherein the anti-connexin 43 agent inhibits or blocks connexin 43 hemichannel opening.

13. The method of claim 1, wherein said method further comprises administration of second composition comprising one or more therapeutic agents.

14. The method of claim 1, wherein said method further comprises administration of second composition comprising one or more agents useful for wound healing.

15. The method of claim 1, wherein said method further comprises administration of second composition comprising one or more anti-microtubule agents.

16. The method of any one of claims 13-15, wherein the second composition is administered before, after or simultaneously with the first composition.

17. The method of any one of claims 13-15, wherein the second composition is administered before and after the first composition.

39. The method of claim 66 wherein the anti-connexin 43 agent is a peptide compound.

66. A method of any of claim 1, 18, 34 or 51 wherein, abnormal tissue formation inside and/or around a joint is prevented or decreased.

18. A method of decreasing pain in a post-orthopedic-surgical subject comprising administration of a composition comprising an anti-connexin 43 agent during or at the conclusion of said surgery.

19. The method of claim 18, wherein the anti-connexin 43 agent is an anti-connexin 43 polynucleotide.

20. The method of claim 19, wherein the anti-connexin 43 polynucleotide decreases connexin 43 protein expression.

21. The method of claim 19 wherein the anti-connexin 43 polynucleotide is an antisense oligonucleotide.

22. The method of claim 19 wherein the anti-connexin 43 polynucleotide is an siRNA or RNAi oligonucleotide.

23. The method of claim 18 wherein the anti-connexin 43 agent is a peptide.

24. The method of claim 30 wherein the peptide is a peptidomimetic.

25. The method of claim 18, wherein the anti-connexin 43 agent is an anti-connexin 43 antibody or antigen binding fragment thereof.

26. The method of claim 32, wherein the anti-connexin 43 agent is an antibody, F(v) fragment, Fab fragment, Fab′

fragment or F(ab′

)₂ fragment.

27. The method of claim 18, wherein the anti-connexin 43 agent inhibits or blocks intercellular communication.

28. The method of claim 18, wherein the anti-connexin 43 agent inhibits or blocks connexin 43 hemichannel opening.

29. The method of claim 18, wherein said method further comprises administration of second composition comprising one or more therapeutic agents.

30. The method of claim 18, wherein said method further comprises administration of second composition comprising one or more agents useful for wound healing.

31. The method of claim 18, wherein said method further comprises administration of second composition comprising one or more anti-microtubule agents.

32. The method of any one of claims 29-31, wherein the second composition is administered before, after or simultaneously with the first composition.

33. The method of any one of claims 29-31, wherein the second composition is administered before and after the first composition.

41. The method of claim 24, wherein the anti-connexin 43 agent is an anti-connexin 43 antibody, F(v) fragment, Fab fragment, Fab′

fragment or F(ab′

)₂ fragment.

34. A method of treating and/or preventing, in whole or in part, post-orthopedic-surgical joint contracture in a subject by administering a composition comprising an anti-connexin 43 agent to said subject during or after said orthopedic surgery.

35. The method of claim 34, wherein the anti-connexin 43 agent is an anti-connexin 43 polynucleotide.

36. The method of claim 35, wherein the anti-connexin 43 polynucleotide decreases connexin 43 protein expression.

37. The method of claim 35 wherein the anti-connexin 43 polynucleotide is an antisense oligonucleotide.

38. The method of claim 35 wherein the anti-connexin 43 polynucleotide is an siRNA or RNAi oligonucleotide.

42. The method of claim 34, wherein the anti-connexin 43 agent inhibits or blocks intercellular communication.

43. The method of claim 34, wherein the anti-connexin 43 agent inhibits or blocks connexin 43 hemichannel opening.

44. The method of claim 34, wherein said method further comprises administration of second composition comprising an anti-connexin agent.

45. The method of claim 34, wherein said method further comprises administration of second composition comprising one or more therapeutic agents.

46. The method of claim 34, wherein said method further comprises administration of second composition comprising one or more agents useful for wound healing.

47. The method of claim 34, wherein said method further comprises administration of second composition comprising one or more anti-microtubule agents.

48. The method of any one of claims 44-47, wherein the second composition is administered before, after or simultaneously with the first composition.

49. The method of any one of claims 44-47, wherein the second composition is administered before and after the first composition.

50. A method of claim 34, wherein abnormal tissue formation inside and/or around a joint is prevented or decreased.

40. The method of claim 73 wherein the peptide compound is a peptidomimetic.

51. A method of treating a subject having or suspected of having or predisposed to, or at risk for an orthopedic disease, disorder, or condition characterized in whole or in part by abnormal tissue formation inside and/or around a joint, comprising administering a composition comprising an effective amount of an anti-connexin 43 agent.

52. The method of claim 51, wherein the anti-connexin 43 agent is an anti-connexin 43 polynucleotide.

53. The method of claim 52, wherein the anti-connexin 43 polynucleotide decreases connexin 43 protein expression.

54. The method of claim 52 wherein the anti-connexin 43 polynucleotide is an antisense oligonucleotide.

55. The method of claim 52 wherein the anti-connexin 43 polynucleotide is an siRNA or RNAi oligonucleotide.

56. The method of claim 51 wherein the anti-connexin 43 agent is a peptide compound.

57. The method of claim 56 wherein the peptide compound is a peptidomimetic.

58. The method of claim 51, wherein the anti-connexin 43 agent is an anti-connexin 43 antibody, F(v) fragment, Fab fragment, Fab′

fragment or F(ab′

)₂ fragment.

59. The method of claim 51, wherein the anti-connexin agent inhibits or blocks intercellular communication.

60. The method of claim 51, wherein the anti-connexin agent inhibits or blocks connexin 43 hemichannel opening.

61. The method of claim 51, wherein said method further comprises administration of a second composition comprising one or more therapeutic agents.

62. The method of claim 51, wherein said method further comprises administration of a second composition comprising one or more agents useful for wound healing.

63. The method of claim 51, wherein said method further comprises administration of second composition comprising one or more anti-microtubule agents.

64. The method of any one of claims 61-63, wherein the second composition is administered before, after or simultaneously with the first composition.

65. The method of any one of claims 61-63, wherein the second composition is administered before and after the first composition.